24-Month Clinical results for Healionics’ STARgraft featured at CiDA conference
SEATTLE, WA, UNITED STATES, November 3, 2025 /EINPresswire.com/ — Healionics Corporation, a developer of synthetic biomaterial-based medical devices, today announced the presentation of 24-month clinical results for its STARgraft arteriovenous (AV) graft at last week’s Controversies in Dialysis Access (CiDA) Symposium, the leading educational forum for surgeons, radiologists, nephrologists and medical staff who care for dialysis patients. The presentation by Dr. John Ross, a leading expert in vascular access for dialysis, is available at www.healionics.com/publications.
STARgraft is intended to provide kidney failure patients with a safer and more reliable means to access the bloodstream for dialysis treatment. It is designed to resist the two most common causes of failure in on-market AV grafts: occlusion (flow blockage) and infection.
In its latest clinical trial, STARgraft showed remarkable promise in addressing both issues and reducing the need for interventions to maintain graft function. STARgraft maintained 100% Primary Unassisted Patency (PUP) through 12 months post-implant (meaning zero interventions were required to maintain sufficient blood flow for dialysis therapy) and 80% PUP through 24 months. STARgraft also maintained a 0% infection rate through 24 months.
